Sysmex Unveils Promising Blood-Based Alzheimer’s Biomarker Data at CTAD 2025
I'm PortAI, I can summarize articles.
Sysmex Corporation will present new clinical research on blood-based biomarkers for Alzheimer's Disease at the 18th Clinical Trials on Alzheimer’s Disease conference (CTAD) in December 2025. The presentations will include data on APOE genotyping PCR test, MTBR-tau fragment assay, plasma pTau217/Aβ42 ratios, and HISCL-5000 plasma assays. Collaborative studies on plasma Aβ42/40 and p-tau217 for predicting amyloid pathology will also be featured.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments